Rise Advisors’s Maravai LifeSciences MRVI Stock Holding History

Rise Advisors’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-50	Closed	-$701	–	755
2023 Q1	$701	Hold	50	–	–	﹤0.01%	701
2022 Q4	$716	Hold	50	–	–	﹤0.01%	685
2022 Q3	$1K	Hold	50	–	–	﹤0.01%	647
2022 Q2	$1K	Hold	50	–	–	﹤0.01%	649
2022 Q1	$2K	Buy	+50	New	+$1.68K	﹤0.01%	544

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Rise Advisors's MRVI Position: Q2 2023 in Review

Rise Advisors sold out of Maravai LifeSciences (MRVI) in Q2 2023, closing a stake of 50 shares — an estimated $701 sold.

Rise Advisors first reported a position in MRVI in Q1 2022 and held it in 5 quarters. The position peaked at $2K in Q1 2022. 221 funds tracked by Wall St. Rank hold MRVI as of Q2 2023.

Rise Advisors reported no remaining Maravai LifeSciences position as of Q2 2023 after selling out during the quarter.
Rise Advisors sold 50 Maravai LifeSciences shares in Q2 2023, an estimated $701.
Rise Advisors first reported a position in Maravai LifeSciences in Q1 2022 and held it in 5 quarters.
Rise Advisors's Maravai LifeSciences position peaked at $2K in Q1 2022.
221 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2023.

Based on Rise Advisors's 13F filing for Q2 2023, filed 10 Jul 2023.